QSAM Biosciences adds nuclear reactor at University of Texas to supply chain

QSAM Biosciences announced the qualification and addition of the nuclear reactor at the University of Texas at Austin to its supply chain for the production of Samarium-153, the active radioisotope used in QSAM‘s therapeutic radiopharmaceutical drug candidate, CycloSam, a potentially groundbreaking treatment for metastatic and primary bone cancer in adults and children. QSAM is actively enrolling patients with metastatic bone cancer in a Phase I clinical trial across four clinical research centers in the United States. The qualification of the nuclear reactor at UT-Austin, QSAM’s second qualified reactor, increases the availability of Samarium-153 and provides logistical efficiencies for the production and administration of CycloSam for current and future clinical trials, as well as the commercial supply of CycloSam if ultimately approved by the FDA.